Franco Valle appointed chief financial officer at Biomea fusion in move to strengthen company’s executive team

USA – Biomea Fusion, a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer.

Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies.

He will assume the financial leadership from Sunny Lee who has served at that role since September2020.

Recently, Mr. Valle served as Principal Accounting Officer & Senior Vice President of Finance at Eidos, a former publicly traded, clinical-stage biopharmaceutical company, which merged with BridgeBio for US$2.83 Billion earlier in 2021.

Prior to Eidos, Mr. Valle served as the Principal Accounting Officer and Controller at Lovance Biotherapeutics from 2016 until 2018.

Mr. Valle also worked at Pharmacyclics, which he joined in 2012 and supported through its merger with Abbvie as Senior Accounting Officer of the company.

He is a certified public accountant and started his career in 2005 at Pricewaterhouse Coopers LLP(PWC), where he spent six years in the Life Science, Biotech and Venture Capital Group.

“I have worked together with Franco in the past, and I could not be happier he joined as the CFO of Biomea,” said Eric Aguiar, M.D., Lead Director and Chairman of the Audit Committee at Biomea. “Franco is very knowledgeable, structured, and will help Biomea continue to build organizational systems to grow and support the full clinical exploration of Biomea’s portfolio of small molecules.”

“I am thrilled to join Biomea, particularly on the heels of its successful IPO in April and strong pipeline of clinical catalysts. I have worked with many of the leadership in the past and know first-hand their track record and commitment to develop novel irreversible small molecules that transform treatments in a targeted, patient friendly manner,” said Mr. Valle.

Mr. Valle will be joined by Terrie Phan, who will become Vice President and Corporate Controller of Biomea.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.